Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,584 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Diabetes Mellitus, Juvenile-Onset Clear all

Conditions: Type 1 Diabetes
Interventions: iAPS, Sensor-Augmented Pump; Device · Other
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Santa Barbara, California • Rochester, Minnesota

Conditions: Type 1 Diabetes Mellitus
Interventions: teplizumab, Placebo; Biological
Lead sponsor: Provention Bio, Inc.; Industry
Eligibility: 8 Years to 17 Years
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 34
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 30 more

Conditions: Type 1 Diabetes
Interventions: Parent education with human patient simulator, Standard care; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Diabetes Mellitus, Type 1
Interventions: Technosphere insulin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes Mellitus
Interventions: Sansum Closed-Loop Artificial Pancreas, Insulin infusion pump, Continuous Glucose Monitor, zone-Model Predictive Control algorithm, Safety Health Monitoring System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes Mellitus, Type 1
Interventions: Teplizumab, Placebo; Biological · Other
Lead sponsor: Provention Bio, a Sanofi Company; Industry
Eligibility: 9 Years to 19 Years
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Walnut Creek, California + 22 more

Conditions: Lupus Erythematosus, Rheumatoid Arthritis, Type 1 Diabetes
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes
Interventions: Financial Incentives Program; Behavioral
Lead sponsor: Harvard Pilgrim Health Care; Other
Eligibility: 12 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes (T1D)
Interventions: The T1D Talks: A Virtual Group for Teens and Tweens with T1D; Behavioral
Lead sponsor: Western Michigan University School of Medicine; Other
Eligibility: 12 Years to 14 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Diabetes Mellitus, Type 1, Diabetes Complications
Interventions: Device specific training, Study clinician/educator visit; Device · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts • The Bronx, New York

Conditions: Diabetes Mellitus, Type 1
Interventions: Placebo, PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C, PF-06342674 Dose D; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: San Diego, California • San Francisco, California • Aurora, Colorado + 7 more

Conditions: Type 1 Diabetes
Interventions: HIT-aided approach, Contracted conflict management system, HIT plus contracted conflict management; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 12 Years to 18 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: University of South Florida; Other
Eligibility: 2 Years to 45 Years
Enrollment: 75,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2030
U.S. locations: 17
States / cities: Orange, California • San Francisco, California • Stanford, California + 14 more

Conditions: Type 1 Diabetes
Interventions: Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400; Drug · Device
Lead sponsor: Medtronic MiniMed, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 5
States / cities: Santa Barbara, California • Aurora, Colorado • North Kansas City, Missouri + 2 more

Conditions: Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions: Control:Diabetes mobile app; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: InPen Insulin Pen; Device
Lead sponsor: Wayne State University; Other
Eligibility: 13 Years to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Tumor, Solid
Interventions: Durvalumab and Tremelimumab; Drug
Lead sponsor: John L. Villano, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Diabetes Mellitus, Diabetes Type 1
Interventions: ACZ885, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 35 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diabetes Mellitus, Type 1
Interventions: Parent mentors; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 10 Years to 15 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: INGAP Peptide; Drug
Lead sponsor: GMP Endotherapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 4
States / cities: San Diego, California • Washington D.C., District of Columbia • Durham, North Carolina + 1 more

Conditions: Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin, Pramlintide + Insulin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 12 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: Plan, Reflect, and Engage with Providers for Diabetes Care; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 17 Years to 23 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Artificial Pancreas With Different Stress Assessments in the Outpatient Setting

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

PETS-D (Parent Education Thru Simulation-Diabetes)

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study

Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS)

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Analysis of B Cells From Autoimmune Individuals

InvesT1D: Promoting Adolescent Investment in Diabetes Care

The T1D Talks Pilot Study

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Advancing Diabetes Management in Adolescents Using Health Information Technology

TrialNet Pathway to Prevention of T1D

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

Control:Diabetes Pilot Study I

Evaluating the InPen in Pediatric Type 1 Diabetes

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

ACZ885 in Type 1 Diabetes Mellitus

Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care

Improving Diabetes Equity and Advancing Care Study